Linagliptin is a recent addition to the dipeptidyl peptidase IV (DPP-IV) inhibitor family. Approved by the FDA in 2011, linagliptin is used to treat type 2 diabetes by stimulating the pancreas to produce insulin.
Brand names: Linagliptin is marketed as Tradjenta.
Drug class: Tradjenta belongs to a class of drugs known as dipeptidyl peptidase IV (DPP-IV) inhibitors. DPP-IV inhibitors are designed to break down incretin hormones (GLP-1 and GIP), which signals the pancreas to increase the production of insulin.
Other medications classified as DPP-IV inhibitors include these:
Dosage: Tradjenta comes in an oral tablet and is typically taken once daily, with or without food. The recommended dosage for adults is 5 mg. Individuals with type 1 diabetes should not take Tradjenta.
Side effects: The most common side effects of linagliptin are runny or stuffy nose, headache and joint pain.